Description
|
Catalog #
|
CAS#
|
Target
|
Size
|
Price ( $)
|
Casein Kinase I Inhibitor, D4476
CK1 Inhibitor,
4-(4-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide
|
SMBC1066
|
301836-43-1
|
A cell-permeable triaryl substituted
imidazolo compound that acts as a
potent, reversible and relatively specific
ATP-competitive inhibitor of CK1 (IC50 =
0.2 µM from S. pombe; 0.3 µM for CK1δ)
and ALK5 (IC50 = 0.5 µM).
|
1 mg
|
120
|
MMP-2/MMP-9 Inhibitor I
(2R)-2-[(4-Biphenylylsulfonyl)amino]-3-phenylpropionic Acid
|
SMBC1067
|
193807-58-8
|
A potent inhibitor of MMP-2 (IC50 = 310
nM) and MMP-9 (IC50 = 240 nM). Orally
active in animal models of tumor growth
and metastasis.
|
5 mg
|
145
|
Purvalanol A
2-(1R-Isopropyl-2-hydroxyethylamino)-6-(3-chloroanilino)-9-isopropyl-purine
|
SMBC1069
|
212844-53-6
|
A potent, cell-permeable, reversible, and
selective inhibitor of cyclin-dependent
kinases (Cdks; IC50 = 4 nM for
Cdc2/cyclin B; IC50 = 70 nM for
Cdk2/cyclin A; IC50 = 35 nM for
Cdk2/cyclin E; and IC50 = 75 nM for
Cdk5/p35).
|
1 mg
|
60
|
Purvalanol A
2-(1R-Isopropyl-2-hydroxyethylamino)-6-(3-chloroanilino)-9-isopropyl-purine
|
SMBC1069
|
212844-53-6
|
A potent, cell-permeable, reversible, and
selective inhibitor of cyclin-dependent
kinases (Cdks; IC50 = 4 nM for
Cdc2/cyclin B; IC50 = 70 nM for
Cdk2/cyclin A; IC50 = 35 nM for
Cdk2/cyclin E; and IC50 = 75 nM for
Cdk5/p35).
|
5 mg
|
120
|
Cell Sheet Migration Inhibitor, Locostatin
|
SMBC1071
|
133812-16-5
|
A cell-permeable
N-(crotonyl)oxazolidinone compound
that acts as a potent inhibitor of Raf
kinase inhibitor protein (RKIP)/Raf1
kinase interaction. Shown to block
eukaryotic cell migration (IC50 = 14 µM
for inhibition of wound closure in MDCK
cell monolayers) and decrease
formation of lamellipodial protrusions at
the wound margin.
|
10 mg
|
115
|
PDGFR Tyrosine Kinase Inhibitor III
4-(6,7-Dimethoxy-4-quinazolinyl)-N-(4-phenoxyphenyl)-1-piperazinecarboxamide
|
SMBC1072
|
205254-94-0
|
A cell-permeable piperazinyl-quinazoline
carboxamide compound that acts as a
potent, ATP-competitive, reversible, and
selective inhibitor of PDGF receptor
family of tyrosine kinases (IC50 = 0.05
µM for α-PDGFR; 0.08 µM for β-PDGFR;
0.05 µM for c-Kit; 0.23 µM for Flt3).
|
1 mg
|
102
|
1400W
N-(3-Aminomethyl)benzylacetamidine, 2HCl
|
SMBC1075
|
214358-33-5
|
A selective, cell-permeable, irreversible,
slow, tight-binding inhibitor of inducible
nitric oxide synthase (iNOS; Kd = 7 nM).
Suitable for use in both in vitro and in
vivo systems.
|
5 mg
|
102
|
TGF-β RI Kinase Inhibitor II
ALK5 Inhibitor II, Transforming Growth Factor-β Type I Receptor Kinase Inhibitor
II, 2-(3-(6-Methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine
|
SMBC1076
|
|
A cell-permeable naphthyridinyl pyrazolo
compound that acts as a potent,
selective, reversible, and ATP-
competitive inhibitor of TGF-β type I
receptor (ALK5; IC50 = 23 nM, 4 nM and
18 nM for ALK5 binding, ALK5 auto-
phosphorylation and TGF-β cellular
assay in HepG2 cells, respectively).
|
1 mg
|
102
|
NDSB-256-4T
SB256-4T, SN2564T, 3-(4-tert-Butyl-1-pyridino)-1-propane Sulfonate
|
SMBC1077
|
|
A non-detergent sulfobetaine (NDSB)
that prevents protein aggregation and
facilitates protein-folding, presumably by
interacting with the early folding
intermediates.
|
5 gm
|
128
|
CL 82198
|
SMBC1079
|
|
A selective inhibitor of MMP-13 (IC50 =
10 µM). Binds to the S1′ pocket of MMP-
13 with its morpholine ring adjacent to
the catalytic zinc atom.
|
5 mg
|
95
|
Tranilast
N-(3′,4′-Dimethoxycinnamoyl)anthranilic Acid
|
SMBC1080
|
53902-12-8
|
An anthranilic acid analog that acts as a
potent inhibitor of VEGF- and vascular
permeability factor-induced
angiogenesis and collagen synthesis.
Inhibits VEGF- and PMA-stimulated PKC
activity in retinal capillary endothelial
cells without affecting the VEGF binding
or VEGF receptor phosphorylation.
|
10 mg
|
95
|
5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole
5,6-Dichlorobenzimidazole Riboside, DRB
|
SMBC1081
|
53-85-0
|
A potent, ATP-competitive, and specific
inhibitor of casein kinase II (IC50 = 6
µM). Reported to inhibit
insulin-stimulated nuclear and cytosolic
p70S6 kinase in CHO cells.
|
50 mg
|
95
|
BAPTA, Tetrasodium Salt
|
SMBC1082
|
126824-24-6
|
Ca2+ chelator exhibiting a 105-fold
greater affinity for Ca2+ (Kd = 110 nM)
than for Mg2+. After BAPTA complexes
with Ca2+, the UV spectrum shifts from
254 to 279 nm at pH >6.0. Useful for
spectrophotometric monitoring of
extracellular Ca2+ levels, especially
transient phenomena, because of its
insensitivity to pH.
|
1 gm
|
110
|
JNK Inhibitor II, Negative Control
N¹-Methyl-1,9-pyrazoloanthrone
|
SMBC1088
|
|
A useful negative control for JNK
Inhibitor II (SP600125, Cat. No. 420119).
Inhibits JNK2 and JNK3 only at much
higher concentrations (IC50 = 18 µM
and 24 µM, respectively) compared to
SP600125 (IC50 = 40 nM and 90 nM,
respectively).
|
1 mg
|
58
|
IKK-2 Inhibitor VI
(5-Phenyl-2-ureido)thiophene-3-carboxamide
|
SMBC1090
|
354811-10-2
|
An ureido-thiophenecarboxamide
compound that acts as a potent,
cell-permeable, reversible, and
ATP-competitive inhibitor of IKK-2 (IC50
= 13 nM).
|
1 mg
|
120
|
Compound 56
4-[(3-Bromophenyl)amino]-6,7-diethoxyquinazoline
|
SMBC1094
|
171745-13-4
|
A cell-permeable, reversible,
ATP-competitive, highly potent and
specific inhibitor of the tyrosine kinase
activity of the epidermal growth factor
receptor (IC50 = 6 pM).
|
500 μg
|
140
|
(±)-Blebbistatin
|
SMBC1095
|
674289-55-5
|
A cell-permeable compound that acts as
a selective, potent, and reversible
inhibitor of nonmuscle myosin II. Inhibits
the ATPase and gliding motility of
human platelets (≤ 100 µM) without
affecting myosin light chain kinase
(MLCK) activity.
|
5 mg
|
145
|
Cathepsin G Inhibitor I
Z-Phe-Gly-NHO-Bz
|
SMBC1098
|
|
A potent, selective, reversible,
competitive, non-peptide inhibitor of
cathepsin G [IC50 = 53 nM and Ki = 63
nM].
|
1 mg
|
125
|
